All material subject to strictly enforced copyright laws. © 2021 Euromoney Institutional Investor PLC group
EquityEquity IPOs

PharmaSGP reduces IPO size because of market volatility

Pharma_natural_medecine_adobe_575x375.jpg

The IPO of PharmaSGP, the German manufacture of natural drugs and medicines, was a smaller affair than had been originally envisaged by the sellers, after the return of equity market volatility meant that the deal had to be priced at the bottom of the range.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree